Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma.
| Autor: | Karaoğullarindan Ü; Gastroenterology Department, Cukurova University, Adana, Turkey., Gümürdülü Y, Üsküdar O, Odabaş E, Güler HS, Tozluklu N, Bağir E, Kuran S |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2023 Jan 01; Vol. 35 (1), pp. 89-93. Date of Electronic Publication: 2022 Sep 12. |
| DOI: | 10.1097/MEG.0000000000002452 |
| Abstrakt: | Objectives: Hepatocellular carcinoma (HCC) is the seventh most common cancer all worldwide and is second in cancer-related deaths. In HCC, whose prognosis is still not good despite current treatments, there is a need for prognostic markers as well as early diagnosis. Glypican (GPC)-3 has been proposed as a potential serologic and histochemical marker specific to HCC. This study aimed to determine the relationship between GPC3 overexpression and HCC prognosis and clinicomorphologic features. Materials and Methods: In total 152 patients who were diagnosed as a result of hepatectomy, lobectomy or liver transplantation were enrolled. The patients were divided into two groups, GPC3-positive (overexpression) (>10%) and GPC3-negative (<10%). The demographic data of the patients, tumor characteristics and survival times were recorded. Results: Survival was significantly lower in the GPC3+ group. In the multivariate analysis, hepatitis C, AFP, tumor number, tumor focality, portal vein tumor thrombosis and GLP3 positivity were found to be independent risk factors for survival. Conclusion: Our study shows that GPC3 overexpression is a poor prognostic factor in HCC. GPC3 positivity were found to be an independent risk factor for survival. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|